Last updated on October 2018

IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients

Brief description of study

IoN is a phase II/ III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.

Detailed Study Description

Phase II: to determine if recruitment into a phase III trial is feasible, with a target of 10 patients per month during a minimum of 6 months (evaluated within months 7-18 of the trial).

Phase III: to determine whether the 5-year disease-free survival rate among patients who do not have routine Radioactive iodine (RAI) ablation is non-inferior to those who do.

Clinical Study Identifier: NCT01398085

Find a site near you

Start Over

Imperial College Healthcare NHS Trust

London, United Kingdom
  Connect »

Royal Marsden NHS Foundation Trust

London, United Kingdom
  Connect »